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Quality of Life after Lung Cancer Surgery: A Prospective
Pilot Study comparing Bronchial Sleeve Lobectomy
with Pneumonectomy
Bram Balduyck, MD, Jeroen Hendriks, MD, PhD, Patrick Lauwers, MD,
and Paul Van Schil, MD, PhD
Objective: To prospectively evaluate quality of life (QoL) evolution
after sleeve lobectomy and pneumonectomy with the European
Organisation for Research and Treatment of Cancer (EORTC) QoL
Questionnaire-C30 and LC-13.
Methods: From January 2003 till December 2005, QoL was pro-
spectively recorded after 10 sleeve lobectomies and 20 pneumonec-
tomies. Questionnaires were administered before surgery and 1, 3, 6,
and 12 months postoperatively (MPO) with response rates of 100%,
90.0%, 76.7%, 80.0% and 73.3%, respectively.
Results: Sleeve lobectomy was characterized by a 1 month tempo-
rary decrease in physical and social functioning scores after surgery
(1MPO p  0.026 and p  0.048, respectively). After sleeve
lobectomy, quality of life scores approximated baseline preoperative
values 1 month after surgery.
In the 12 months follow-up period after pneumonectomy, there
was no return to baseline in physical and role functioning (12MPO p
0.001 and p  0.011, respectively). Pneumonectomy patients reported
a significant increase in postoperative dyspnea (1MPO p  0.027,
6MPO p  0.025, 12MPO 0.021), general pain (1MPO p  0.006,
3MPO p 0.008, 6MPO p 0.005, 12MPO p 0.036), thoracic pain
(6MPO p 0.019) and shoulder dysfunction (6MPO p 0.04, 12MPO
p  0.026).
Comparing both resections, significant differences in evolution
of physical functioning (1MPO p  0.014, 3MPO p  0.008, 6MPO
p 0.004), role functioning (1MPO p 0.041), cognitive functioning
(6MPO p  0.005, 12MPO p  0.013) and shoulder dysfunction
(12MPO p  0.049) were reported in favor of sleeve lobectomy.
Conclusions: The high burden of dyspnea, general pain, thoracic
pain and shoulder dysfunction reported after pneumonectomy, is not
seen after sleeve lobectomy. In patients with anatomically appropri-
ate early-stage lung cancer, sleeve lobectomy offers better quality of
life than does pneumonectomy.
Key Words: Quality of life, EORTC, QLQ-C30, QLQ LC-13,
Bronchial sleeve lobectomy, Pneumonectomy, Lung cancer.
(J Thorac Oncol. 2008;3: 604–608)
Bronchial sleeve lobectomy is a lung parenchyma savingprocedure indicated for central tumors and represents an
alternative to pneumonectomy. Recent studies suggest that
sleeve resection should be used routinely in the management
of patients with anatomically appropriate centrally located
tumors, even in patients with sufficient pulmonary reserve to
permit pneumonectomy.1–9 The long-term survival after
sleeve lobectomy is favorable to that after pneumonectomy
with lower postoperative risks and better preservation of lung
function.10–13 Pneumonectomy is associated with significant
morbidity and mortality,10–14 including postpeumonectomy
lung edema, acute respiratory distress syndrome (ARDS),
bronchopleural fistula, and postpeumonectomy syndrome. A
recent meta-analysis of Zhiyuan Ma et al. demonstrated that
sleeve lobectomy is effective and can be accomplished safely
in selected patients without increasing the morbidity and
mortality when compared with pneumonectomy.10
The aim of any cancer treatment extends well beyond
increasing survival. Palliation of symptoms and the mainte-
nance or improvement of quality of life (QoL) are equally
important goals of treatment. The benefits of existing cancer
treatment need to be weighed against the side-effects and
possible impairment of patients’ QoL. For many patients, the
risk of an impaired QoL after surgery is an important con-
sideration when deciding whether to proceed with surgery.
Some patients may regard immediate postoperative compli-
cations as an acceptable risk, but are not prepared to accept
significant postoperative functional disability.15 The last few
decades, there has been an increased recognition of the need
to complement surgical treatment with an assessment of QoL,
in addition to the impact of treatment, survival and side
effects. Collection of postoperative QoL data has been advo-
cated in follow-up of patients with cancer16 and most pub-
lished studies encourage the assessment of QoL in evaluating
treatment outcomes.15,17 In clinical lung cancer trials, several
instruments have been validated, including the European
Organisation for Research and Treatment of Cancer Quality
of Life Questionnaire (EORTC QLQ).18 Limited information
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is available regarding the long-term QoL evolution after
bronchial sleeve lobectomy. The objective of the present
study is to prospectively evaluate QoL evolution after sleeve
lobectomy and pneumonectomy for lung cancer, which has
not been studied prospectively until now.
PATIENTS AND METHODS
From January 2003 to December 2005, 30 consecutive
patients with a clinical diagnosis of non-small cell lung
cancer (NSCLC) underwent bronchial sleeve lobectomy (n
10) or pneumonectomy (n20). Sixteen patients underwent a
left pneumonectomy and four patients a right pneumonec-
tomy. Sleeve lobectomy was considered and performed in
any case that could be completely resected by this technique.
Pneumonectomy was performed for lesions that could not be
removed by a lesser bronchoplastic procedure. Patients’ char-
acteristics for the two surgical procedures are listed in Table 1.
Quality of Life Assessment
QoL was assessed using the Dutch version of the
European Organisation for Research and Treatment of Cancer
(EORTC) Quality of Life Questionnaire (QLQ)-C30 (cancer
core questionnaire) and the Dutch version of the EORTC
QLQ-LC13 lung cancer-specific questionnaire module.18,19
The questionnaires were administered one day before surgery
and at 1, 3, 6, and 12 months postoperatively. The question-
naires were sent to the patients by mail, accompanied by a
letter with general information and the aim of the study.
EORTC QLQ-C30
The EORTC QLQ-C30 is a self-rating questionnaire
composed of 30 questions/items and incorporates 9 multi-
item scales: five functional scales (physical, role, cognitive,
emotional, and social), three symptom scales (fatigue, pain,
nausea/vomiting), a global health/QoL scale, and several
single items assessing additional symptoms (dyspnea, sleep
disturbance, constipation, and diarrhea). A final item evalu-
ates the perceived economic consequences of the disease.18
Reliability and validity of the EORTC QLQ-C30 question-
naires have been confirmed in international studies.19,20
EORTC QLQ-LC13
The EORTC QLQ-LC13 is a supplementary question-
naire module that was designed for use among patients
receiving treatment with chemotherapy and/or radiotherapy.
It contains 13 questions/items assessing lung cancer-associ-
ated symptoms (cough, hemoptysis, dyspnea, and site-spe-
cific pain), chemotherapy/radiotherapy-related side effects
(sore mouth, dysphagia, peripheral neuropathy, and alopecia),
and pain medication.21 Chemotherapy/radiotherapy-related
side-effects were not included in the analysis. Reliability and
validity of the EORTC-LC13 module have been confirmed in
international studies.18–20
Statistical Analysis
Statistical analysis was performed using statistical soft-
ware (SPSS, version 15.0, Chicago, IL). In accordance with
procedures recommended by the EORTC, scores were lin-
early converted to a scale ranging from 0 and 100 for each
patient. For the global health/QoL and functional scales,
higher scores represent a higher level of functioning. For the
symptom scales, higher scores represent a greater symptom
burden. Results were reported as mean. The Wilcoxon-signed
rank test was used to compare the mean value before and after
surgery. A Student’s t-test was used to compare parametric
QoL data between groups. The Mann-Whitney U test was
performed to compare nonparametric QoL data between groups.
A p value of less than 0.05 was considered as statistically
significant.
RESULTS
Response Rate to QoL Questionnaire and
Comparison of Patients’ Groups
The preoperative response rate to the QoL question-
naire was 100%, at 1 month 90.0%, at 3 months 80.0%, at 6
months 80.0%, and at 12 months 70.0% in the sleeve lobec-
tomy group. The preoperative response rate was 100%, at 1
month 90.0%, at 3 months 75.0%, at 6 months 80.0%, and at
12 months 75.0% in the pneumonectomy group. No statistical
differences were observed between the sleeve lobectomy and
pneumonectomy group regarding age, sex, adjuvant therapy,
TNM classification, tumor histology and response rate, with
exception of a borderline significant higher number of
T3N1M0 tumors in the sleeve lobectomy group (p  0.046).
Preoperative QoL
Both resections were comparable in preoperative QoL
subscale scores. In general, patients complained of dyspnea
and coughing and had a median impaired physical, social and
emotional functioning preoperatively. There were no statisti-
cal differences in baseline QoL items between the two resec-
tion groups. QoL at baseline and evolution is shown in Table 2.
Operative Morbidity and Mortality
No operative mortality was observed, neither after
sleeve lobectomy or pneumonectomy. After a mean fol-
low-up of 43.7 months (range, 24–64 months), 5-year sur-
vival rates were 0.60  0.12 in the sleeve lobectomy group
TABLE 1. Patients’ Characteristics
Sleeve
Lobectomy
(n  10)
Pneumonectomy
(n  20)
Age (SD) 65.3  7.3 yr 63.3  10.6 yr
TNM classification
Stage I 2 (20%) 3 (15%)
Stage II 1 (10%) 9 (45%)
Stage III 7 (70%) 8 (40%)
Histology squamous cell carcinoma 6 (60%) 14 (70%)
adenocarcinoma 4 (40%) 6 (60%)
Induction chemotherapy 4 (40%) 5 (25%)
Adjuvant radiotherapy 5 (50%) 4 (20%)
Adjuvant chemotherapy 3 (30%) 4 (20%)
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and 0.66  0.16 in the pneumonectomy group. There was no
significant difference in 5-year survival between both groups.
Regarding morbidity during the first postoperative year, three
patients (30.0%) had pneumonia and three (30.0%) had per-
sistent atelectasis necessitating repeat bronchoscopic treat-
ment after sleeve lobectomy. There was one wound hema-
toma, necessitating arterial ligation in the latissimus dorsi
muscle. Three patients (30.0%) had supraventricular tachy-
cardia. Bronchial stenosis at the site of the anastomosis
developed in two patients (20.0%) requiring several broncho-
scopic dilatations. No patient required completion pneumo-
nectomy. After pneumonectomy, four patients (20.0%) de-
veloped pneumonia at the contralateral side and two patients
(10.0%) had a wound infection. After pneumonectomy, one
immediate reoperation was necessary because of acute hemo-
thorax. Four patients (20.0%) had supraventricular tachycar-
dia. There was one case of vocal cord palsy. In the 12 month
follow-up period, no local recurrences were observed. No
significant difference in postoperative complication rate has
been found between both groups with exception of a signif-
icantly higher occurrence of atelectasis (p  0.011) in the
sleeve lobectomy group.
TABLE 2. Mean Baseline QoL Functioning Scores and Mean Changes from Baseline as Measured by the
EORTC QLQ-C30 and LC-13
Domain
Mean Baseline
QoL Scores
Mean Score Change from Baseline ([Delta]T0a)
1 mo 3 mo 6 mo 12 mo
QoL functioning scoresa
Physical functioning
Sleeve lobectomy 80.6 10.9, p  0.027 1.0 NS 1.9 NS 8.4 NS
Pneumonectomy 89.4 22.7, p  0.000 20.0, p  0.002 19.8, p  0.001 17.3, p  0.001
Role functioning
Sleeve lobectomy 75.1 5.8, p  0.027 8.5 NS 0.1 NS 21.6 NS
Pneumonectomy 88.3 40.6, p  0.000 28.9, p  0.006 32.3, p  0.002 27.7, p  0.011
Emotional functioning
Sleeve lobectomy 83.4 8.3 NS 13.4 NS 2.1 NS 6.0 NS
Pneumonectomy 65.5 14.3 NS 19.4, p  0.020 9.7 NS 2.8 NS
Cognitive functioning
Sleeve lobectomy 83.1 0.2 NS 4.3 NS 8.5, p  0.045 7.3 NS
Pneumonectomy 95.8 7.4 NS 3.3 NS 8.4, p  0.033 20.0, p  0.020
Social functioning
Sleeve lobectomy 78.3 20.2, p  0.048 6.4 NS 10.6 NS 4.9 NS
Pneumonectomy 82.5 4.5 NS 11.0 NS 6.1 NS 11.1 NS
Global Qol
Sleeve lobectomy 62.5 3.6 NS 4.7 NS 8.5 NS 1.1 NS
Pneumonectomy 62.9 10.8 NS 5.3 NS 0.6 NS 7.7 NS
Symptom scoresb
Dyspnea
Sleeve lobectomy 24.9 6.4 NS 0.9 NS 1.3 NS 7.1 NS
Pneumonectomy 16.6 15.7, p  0.027 13.4 NS 16.8, p  0.026 18.4, p  0.021
Coughing
Sleeve lobectomy 24.9 1.8 NS 6.25 NS 6.3 NS 7.2 NS
Pneumonectomy 24.9 4.6 NS 9.9 NS 37.5 NS 8.9 NS
Pain in general
Sleeve lobectomy 12.1 5.1 NS 0.5 NS 4.7 NS 7.1 NS
Pneumonectomy 8.7 11.3, p  0.006 12.5, p  0.008 15.7, p  0.005 13.1, p  0.036
Thoracic pain
Sleeve lobectomy 10.0 0.1 NS 4.1 NS 8.1 NS 9.4 NS
Pneumonectomy 11.6 7.3 NS 4.5 NS 16.9, p  0.019 8.9 NS
Shoulder dysfunction
Sleeve lobectomy 9.9 11.1 NS 0.0 NS 4.1 NS 0.0 NS
Pneumonectomy 3.3 9.3 NS 8.9 NS 14.6, p  0.041 26.3, p  0.026
Enclosed are the p values, indicating significance between the baseline value and the value after 1, 3, 6, and 12 mo. No significance (NS) indicates return
to baseline values.
a Mean changes from baseline: positive numbers indicate a higher functioning score at follow-up (i.e., improvement) compared to baseline, while negative
numbers indicate a reduction in the mean score (i.e., deterioration).
b Mean changes from baseline: positive numbers indicate more symptom burden at follow-up (i.e., deterioration), while negative numbers indicate a
reduction in the symptom burden (i.e., improvement).
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QoL Evolution after Sleeve Lobectomy
Sleeve lobectomy was characterized by a 1 month
temporary decrease in physical and social functioning scores
after surgery. Role function was significantly lower 12
months after surgery. After sleeve lobectomy, global quality
of life, symptom and pain scores approximated baseline
preoperative values 1 month after surgery.
QoL Evolution after Pneumonectomy
Pneumonectomy had a significant impact on physical
and role functioning. In the 12 months follow-up period, there
was no return to baseline in physical and role functioning.
Pneumonectomy patients reported a significant increase in
postoperative dyspnea, general pain, thoracic pain, and shoul-
der dysfunction, not recorded after sleeve lobectomy.
comparing QoL Evolution after Sleeve
Lobectomy and Pneumonectomy
Comparing sleeve lobectomy to pneumonectomy, signif-
icant differences in evolution of physical functioning (1MPO
p 0.014, 3MPO p 0.008, 6MPO p 0.004), role function-
ing (1MPO p  0.041), cognitive functioning (6MPO p 
0.005, 12MPO p  0.013) and shoulder dysfunction (12MPO
p  0.049) were reported in favor of sleeve lobectomy.
DISCUSSION
Bronchoplastic procedures are accepted as an alterna-
tive to pneumonectomy to preserve lung function.2,5 Initially
performed in patients with compromised pulmonary function,
bronchial sleeve lobectomy was progressively adopted by
most thoracic surgeons. Advocates for sleeve lobectomy
point out the disadvantages of pneumonectomy including a
higher occurrence of postoperative complications, cardiopul-
monary dysfunction, long-term morbidity, and a poor QoL.
Five years postoperative results by Deslaurier and colleagues,
indicate that the reimplanted lobe(s) significantly contrib-
ute(s) to the remaining lung function.22 The literature reports
that sleeve lobectomy is followed by similar morbibity and
mortality when compared with pneumonectomy but is asso-
ciated with better lung function preservation.23 In recent
series, operative mortality has ranged from 0% to 5.2% which
is similar to the range after standard lobectomy and lower
than after standard pneumonectomy.1,2,5–7,11,24
Little is known about the QoL evolution in lung cancer
patients who have undergone lung resection. Quality of life in
patients operated for lung cancer tends to deteriorate signif-
icantly with increasing extent of resection. Zieren et al. found
more pronounced breathlessness on effort after pneumonec-
tomy than after lobectomy. When compared with the preop-
erative assessment, QoL had deteriorated on discharge from
hospital but was restored within 3 to 6 months after pneumo-
nectomy.25 Data concerning the QoL after sleeve lobectomy
are rare. Ferguson et al. compared sleeve lobectomy and
pneumonectomy in a meta-analysis of 99 articles and calcu-
lated postoperative quality-adjusted life years (QALY) using
a statistical decision model. The authors concluded that
sleeve lobectomy provides a favorable overall QoL and
QALY advantage to pneumonectomy.1
The present study aimed at determining difference
according to surgical procedure within the first year after
operation using standardized and validated questionnaires,
which has not been studied prospectively until now. Both
resections are comparable in patient characteristics and base-
line QoL, with exception of a higher number of stage III
patients in the pneumonectomy group. Sleeve lobectomy has
a temporary negative impact on physical and social function-
ing scores of 1 month after surgery. After sleeve lobectomy,
quality of life, symptom and pain scores approximated base-
line values 1 month after surgery. In contrast, pneumonec-
tomy has a significant impact on physical and role function-
ing. In the 12 months follow-up period, there is no return to
baseline in physical and role functioning. Pneumonectomy
patients report a significant increase in postoperative dys-
pnea, general pain, thoracic pain, and shoulder dysfunction,
not seen after sleeve lobectomy. Comparing both resections
in QoL evolution, significant differences in evolution of
shoulder dysfunction, physical, role, and cognitive function-
ing are reported in favor of sleeve lobectomy.
The present study has several limitations. A valid and
reliable measurement of QoL is of utmost importance. In the
present study, QoL was assessed by the QLQ-C30 and LC-
13. The reliability and validity of the EORTC questionnaires
have been confirmed in stage III and IV lung cancer patients
only.19,20 It is unknown whether these standardized question-
naires are also applicable to patients who undergo thoracic
surgery. In the present study, 30% of data were missing at 1
year follow-up in both groups. This could introduce a certain
bias. The results of the present study need to be interpreted
with caution because of the rather limited number of patients
included in the study. Larger multicenter prospective studies
comparing both resections need to be planned. In addition,
the patients were not randomized between the two treatment
groups.
This prospective study represents a first step in docu-
menting intermediate to long-term QoL evolution in patients
undergoing bronchial sleeve lobectomy and pneumonectomy.
As both access techniques are not comparable, the results are
not intended to influence the choice of resection technique,
which depends mostly on the specific presentation. Despite
the mentioned limitations, the findings of the study offer
valuable information in understanding the evolution in QoL
after sleeve lobectomy and pneumonectomy and in that way
may create realistic postoperative objectives for patients.
In conclusion, the present pilot study prospectively
documents quality of life evolution profiles comparing pre-
operative status with deficits and changes at 1, 3, 6, and 12
months after sleeve lobectomy and pneumonectomy. With
exception of a 1 month temporary decrease in physical and
social functioning, sleeve lobectomy patients return to their
baseline quality of life in less than 1 month after surgery. In
contrast, pneumonectomy patients report a sustained decrease
of physical and role functioning in the 12-month follow-up
period. The higher degree of dyspnea, general pain, thoracic
pain and shoulder dysfunction reported after pneumonec-
tomy, is not seen after sleeve lobectomy. In patients with
anatomically appropriate early-stage lung cancer, sleeve lobec-
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tomy offers better quality of life than does pneumonectomy. The
authors are grateful to Gina Clerx, Sarah Balduyck and Annelies
Masschelin for their help in the data management.
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